Daclatasvir Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors.Daclatasvir Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Daclatasvir Nitroso CAS NO:NA chemically represented as Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1-nitroso-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate. Synchemia is the leading manufacturing and exporter of Daclatasvir Nitroso . We supply Daclatasvir Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143857 |
| CAS No | NA |
| Mol.F. | C7H5D2ClN4O5S2 |
| Mol.Wt. | 328.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143858 |
| CAS No | NA |
| Mol.F. | C613CH7ClN4O5S2 |
| Mol.Wt. | 327.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143859 |
| CAS No | NA |
| Mol.F. | C613CH5D2ClN215N2O5S2 |
| Mol.Wt. | 331.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143860 |
| CAS No | NA |
| Mol.F. | C613CH5D2ClN4O5S2 |
| Mol.Wt. | 329.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143861 |
| CAS No | NA |
| Mol.F. | C31H43N3O6S |
| Mol.Wt. | 585.76 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143862 |
| CAS No | NA |
| Mol.F. | C31H45N3O6S |
| Mol.Wt. | 587.78 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143863 |
| CAS No | NA |
| Mol.F. | C21H22N2O8S2 |
| Mol.Wt. | 494.53 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143864 |
| CAS No | NA |
| Mol.F. | C31H43N3O7S |
| Mol.Wt. | 601.76 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143865 |
| CAS No | NA |
| Mol.F. | C14H17BrN2O4 |
| Mol.Wt. | 357.20 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143866 |
| CAS No | NA |
| Mol.F. | C26H35N3O4 |
| Mol.Wt. | 453.58 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143867 |
| CAS No | NA |
| Mol.F. | C13H16N2O4S |
| Mol.Wt. | 296.34 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143868 |
| CAS No | NA |
| Mol.F. | C12H14FN3O6 |
| Mol.Wt. | 315.26 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143869 |
| CAS No | NA |
| Mol.F. | C21H38N8O13 : X(H2SO4) |
| Mol.Wt. | 610.6 : X(98.1) g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143870 |
| CAS No | NA |
| Mol.F. | C8H17N7O5 |
| Mol.Wt. | 291.27 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143871 |
| CAS No | NA |
| Mol.F. | C27H50N8O18 |
| Mol.Wt. | 774.74 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143872 |
| CAS No | NA |
| Mol.F. | C21H40N8O12 |
| Mol.Wt. | 596.60 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |